This site is intended only for healthcare professionals resident in the Republic of Ireland
Menu
Close
Menu
Close
XELJANZ inhibits the effects of pro-inflammatory cytokines through intracellular targeting of the JAK pathway3
Please refer to the SmPC before prescribing XELJANZ. Please click here to be directed to the SmPC.
XELJANZ in combination with methotrexate is indicated for the treatment of moderate to severe active rheumatoid arthritis (RA) in adult patients who have responded inadequately to, or who are intolerant to one or more disease-modifying antirheumatic drugs. XELJANZ can be given as monotherapy in case of intolerance to methotrexate (MTX) or when treatment with MTX is inappropriate.1
XELJANZ in combination with MTX is indicated for the treatment of active psoriatic arthritis (PsA) in adult patients who have had an inadequate response or who have been intolerant to a prior disease-modifying antirheumatic drug (DMARD) therapy.1
XELJANZ is indicated for the treatment of adult patients with moderately to severely active ulcerative colitis (UC) who have had an inadequate response, lost response, or were intolerant to either conventional therapy or a biologic agent.1
XELJANZ is indicated for the treatment of adult patients with active ankylosing spondylitis (AS) who have responded inadequately to conventional therapy.1
XELJANZ is indicated for the treatment of active polyarticular juvenile idiopathic arthritis (rheumatoid factor positive [RF+] or negative [RF-] polyarthritis and extended oligoarthritis), and juvenile psoriatic arthritis (PsA) in patients 2 years of age and older, who have responded inadequately to previous therapy with DMARDs.1
Please refer to the XELJANZ Summary of Product Characteristics for full prescribing information
JAK= Janus kinase; MOA= mode of action
Want to see results from the XELJANZ clinical programs?
Learn more about the XELJANZ safety profile
Legal Category: S1A
Further information is available upon request
Adverse events should be reported. Report an adverse event to your national reporting system (HPRA Pharmacovigilance)
Adverse events should also be reported to Pfizer Medical Information on 1800 633 363
Please sign in or register to gain access to information relating to Pfizer medicines and vaccines, medical conditions, patient materials and services.
This site is intended only for healthcare professionals resident in the Republic of Ireland. If you are a member of the public wishing to access information on a specific medicine, please visit https://www.medicines.ie
This website is brought to you by Pfizer Healthcare Ireland, 9 Riverwalk, National Digital Park, Citywest Business Campus, Dublin 24, Ireland. Registered in the Republic of Ireland No. 127002.
Copyright © 2023 Pfizer Limited. All rights reserved.
The information contained on this site is reserved exclusively for healthcare professionals resident in the Republic of Ireland.
I confirm that I am a healthcare professional resident in the Republic of Ireland.*
I accept and agree to the terms of use.*
If you select 'No', you will be redirected to Pfizer.ie, where you will be able to access information on Pfizer Healthcare Ireland.
PP-UNP-IRL-0176. January 2023